<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04594265</url>
  </required_header>
  <id_info>
    <org_study_id>KETO-KINETICS 2 1-10-72-23-20</org_study_id>
    <nct_id>NCT04594265</nct_id>
  </id_info>
  <brief_title>Weight-Adjusted Dosing of 3-OHB in Patients With Chronic Heart Failure</brief_title>
  <acronym>KINETICS2</acronym>
  <official_title>Weight-Adjusted Dosing of 3-OHB in Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to investigate the hemodynamic effects of weight-adjusted dosing of ketone monoester&#xD;
      en patients with chronic heart failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients are studied in a randomized single-blind cross-over design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Output (L/min)</measure>
    <time_frame>5 hours</time_frame>
    <description>Change in Cardiac output measured by Swann-Ganz Catherization during study period,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction</measure>
    <time_frame>5 Hours</time_frame>
    <description>Change in LVEF measured by echocardiography during study periode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Ketones</measure>
    <time_frame>5 hours</time_frame>
    <description>Change in blood Ketones measured by venous blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pH</measure>
    <time_frame>5 hours</time_frame>
    <description>Change in venous blood pH during the study period</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Heart Failure</condition>
  <condition>Ketosis</condition>
  <arm_group>
    <arm_group_label>Ketone Monoester</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US) 0.5 g/kg (max 50 g)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin-based placebo (Science In Sport, UK) in isocaloric dose to the experimental arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketone Monoester in presence of low-dose insulin clamp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Same as experimental arm, but in the presence of a low-dose insulin clamp to suppress free fatty acid metabolism</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>KetoneAid KE4 Pro Monoester</intervention_name>
    <description>A dietary supplement containing ketone monoester.</description>
    <arm_group_label>Ketone Monoester</arm_group_label>
    <arm_group_label>Ketone Monoester in presence of low-dose insulin clamp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Science in Sport Go Enegy</intervention_name>
    <description>Dosis isocaloric to the KetoneAid Arm</description>
    <arm_group_label>Placebo Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: Chronic HF: NYHA class II-III, left ventricular ejection fraction&#xD;
        (LVEF) &lt;40%&#xD;
&#xD;
        Exclusion Criteria: Diabetes or HbA1c &gt;48 mmol/mol, significant cardiac valve disease,&#xD;
        severe stable angina pectoris, severe comorbidity as judged by the investigator, inability&#xD;
        to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristian H Christensen, MD</last_name>
    <phone>+4578452029</phone>
    <email>krstchri@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henrik S Wiggers, DMsci</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristian H Christensen, MD</last_name>
      <email>krstchri@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Kristian Hylleberg Christensen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Hemodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

